Fármacos com potencial terapêutico para tratamento da COVID-19 / Drugs with therapeutic potential for COVID-19 treatment

Authors

  • Luciano de Oliveira Siqueira
  • Augusto Poloniato Gelain
  • Luiz Casemiro Krzyzaniak Grando
  • Luiz Carlos Kreutz

DOI:

https://doi.org/10.34119/bjhrv3n6-153

Keywords:

Infecções por Coronavirus, Hidroxicloroquina, Cloroquina, Antivirais, Antiparasitários, Vacina BCG, Anticoagulantes, Corticosteroides.

Abstract

Objetivos: analisar o potencial terapêutico de fármacos para o manejo da infecção por SARS-CoV-2. Métodos: trata-se de uma revisão bibliográfica realizada em base de dados a respeito dos fármacos utilizados para o manejo do SARS-CoV-2. Resultados: os anti-inflamatórios não-esteroidais (AINES) não mostraram evidências positivas ou negativas, no entanto a administração de corticosteroides mostrou potencial terapêutico promissor quando no estágio avançado da infecção e em déficit respiratório. A transfusão de plasma convalescente e o histórico de imunização com BCG apresentaram-se promissores. Os anticoagulantes podem ser utilizados na tentativa de amenizar a coagulopatia induzida quando em caso de sepse e atividade inflamatória exacerbada. Alguns antiparasitários com efeito antiviral já estabelecido mostraram-se sinérgicos a outras classes farmacológicas. Até o momento os dados científicos mostram a tendência de que os antivirais são mais promissores para o tratamento da COVID-19 que as aminoquinolinas. Conclusão: não há evidências científicas definitivas para o uso de fármacos no tratamento da infecção por SARS-CoV-2. Por outro lado, classes farmacológicas como corticoides, anticoagulantes, antiparasitários e antivirais, demonstraram possíveis benefícios no tratamento da COVID-19. Tais resultados precisam ser melhores compreendidos a partir de novos estudos para entender sua real utilidade nos pacientes com SARS-CoV-2.

References

Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA. Published online April 13, 2020. doi:10.1001/jama.2020.6019

Mocarski ES Jr. Virus self-improvement through inflammation: no pain, no gain. Proc Natl Acad Sci U S A. 2002;99(6):3362-3364. doi:10.1073/pnas.072075899

Cruz-Topete D, Cidlowski JA. One hormone, two actions: anti- and pro-inflammatory effects of glucocorticoids. Neuroimmunomodulation. 2015;22(1-2):20-32. doi:10.1159/000362724

Yang Z, Liu J, Zhou Y, Zhao X, Zhao Q, Liu J. The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis. J Infect. 2020;81(1):e13-e20. doi:10.1016/j.jinf.2020.03.062

Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395(10223):473-475. doi:10.1016/S0140-6736(20)30317-2

Wang Y, Jiang W, He Q, et al. A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia. Signal Transduct Target Ther. 2020;5(1):57. Published 2020 Apr 28. doi:10.1038/s41392-020-0158-2

Mahase Elisabeth. Covid-19: Low dose steroid cuts death in ventilated patients by one third, trial finds BMJ 2020; 369 :m2422. doi: https://doi.org/10.1136/bmj.m2422

Chaiamnuay S, Allison JJ, Curtis JR. Risks versus benefits of cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs. Am J Health Syst Pharm. 2006;63(19):1837-1851. doi:10.2146/ajhp050519

Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271-280.e8. doi:10.1016/j.cell.2020.02.052

Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? [published correction appears in Lancet Respir Med. 2020 Jun;8(6):e54]. Lancet Respir Med. 2020;8(4):e21. doi:10.1016/S2213-2600(20)30116-8.

Capuano A, Scavone C, Racagni G, Scaglione F; Italian Society of Pharmacology. NSAIDs in patients with viral infections, including Covid-19: Victims or perpetrators?. Pharmacol Res. 2020; 157:104849. doi:10.1016/j.phrs.2020.104849

EMA advice on the use of NSAIDs for Covid-19. Drug Ther Bull. 2020;58(5):69. doi:10.1136/dtb.2020.000021

I.F. Hung, K.K. Wang To, J. Chan, K.H. Chan, K.Y. Yuen, ECCMID, O0815 Treatment of Severe Influenza a Infection with Celecoxib, (2019) www.escmid.org.

Gajic O, Rana R, Winters JL, et al. Transfusion-related acute lung injury in the critically ill: prospective nested case-control study. Am J Respir Crit Care Med. 2007;176(9):886-891. doi:10.1164/rccm.200702-271OC

Zhang L, Zhai H, Ma S, Chen J, Gao Y. Efficacy of therapeutic plasma exchange in severe COVID-19 patients [published online ahead of print, 2020 May 26]. Br J Haematol. 2020;10.1111/bjh.16890. doi:10.1111/bjh.16890

Shen C, Wang Z, Zhao F, et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA. 2020;323(16):1582–1589. doi:10.1001/jama.2020.4783

O'Neill LAJ, Netea MG. BCG-induced trained immunity: can it offer protection against COVID-19? Nat Rev Immunol. 2020;20(6):335-337. doi:10.1038/s41577-020-0337-y

Miller A, Reandelar MJ, et al. Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study. medRxiv 2020.03.24.20042937; doi: https://doi.org/10.1101/2020.03.24.20042937

Green, Cameron & Fanucchi, Stephanie & Fok, Ezio & Moorlag, Simone & Domínguez-Andrés, Jorge & Negishi, Yutaka & Joosten, Leo & Netea, Mihai & Mhlanga, Musa. (2020). COVID-19: A model correlating BCG vaccination to protection from mortality implicates trained immunity. 10.1101/2020.04.10.20060905.

Shet A, Ray D, et al. Differential COVID-19-attributable mortality and BCG vaccine use in countries. medRxiv 2020.04.01.20049478; doi: https://doi.org/10.1101/2020.04.01.20049478

Wagstaff KM, Sivakumaran H, Heaton SM, Harrich D, Jans DA. Ivermectin is a specific inhibitor of importin ?/?-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. Biochem J. 2012;443(3):851–856. doi:10.1042/BJ20120150

Caly, L., Druce, J.D., Catton, M.G., Jans, D.A., Wagstaff, K.M., The FDA approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Research, https:// doi.org/10.1016/j.antiviral.2020.104787

Rossignol JF. Nitazoxanide: a first-in-class broad-spectrum antiviral agent. Antiviral Res. 2014; 110:94-103. doi:10.1016/j.antiviral.2014.07.014

Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–271. doi:10.1038/s41422-020-0282-0

Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513. doi:10.1016/S0140-6736(20)30211-7

Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135(23):2033-2040. doi:10.1182/blood.2020006000

Tang, N., Bai, H., Chen, X., Gong, J., Li, D. and Sun, Z. (2020), Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. Accepted Author Manuscript. doi:10.1111/jth.14817

Russo V, Di Maio M, Attena E, et al. Clinical impact of pre-admission antithrombotic therapy in hospitalized patients with COVID-19: A multicenter observational study [published online ahead of print, 2020 May 29]. Pharmacol Res. 2020;159:104965. doi:10.1016/j.phrs.2020.104965)

Ayerbe L, Risco C, Ayis S. The association between treatment with heparin and survival in patients with Covid-19 [published online ahead of print, 2020 May 31]. J Thromb Thrombolysis. 2020;1-4. doi:10.1007/s11239-020-02162-z

Borba MGS, Val F de A, Sampaio VS, Alexandre MAA, Melo GC, Brito M, et al. Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study). medRxiv. 1o de janeiro de 2020;2020.04.07.20056424.

Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, Liu X, Zhao L, Dong E, Song C, Zhan S, Lu R, Li H, Tan W, Liu D; In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).; Clin Infect Dis. 2020

Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–271. doi:10.1038/s41422-020-0282-0

Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: An old drug against today’s diseases? Lancet Infect. Dis. 2003; 3:722–7.

Yan Y, Zou Z, Sun Y, et al. Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model. Cell Res. 2013; 23: 300–2.

Kazi MS, Saurabh K, Rishi P, Rishi E. Delayed onset chloroquine retinopathy presenting 10 years after long-term usage of chloroquine. Middle East Afr J Ophthalmol 2013; 20: 89–91

Silva JA, Silva MB, Skare TL. Chloroquine and QTc interval. Clin Exp Rheumatol; 25: 795.

Chen Z, Hu J, Zhang Z, Jiang S, Han S, Yan D, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv. 1o de janeiro de 2020;2020.03.22.20040758.

Tang w, Cao Z, Han M, et al. Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial. Unpublished. https://www.medrxiv.org/content/10.1101/2020.04.10.20060558v1.full.pdf

Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial [published online ahead of print, 2020 Mar 20]. Int J Antimicrob Agents. 2020;105949. doi:10.1016/j.ijantimicag.2020.105949

Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial Zhaowei Chen, Jijia Hu, Zongwei Zhang, Shan Jiang, Shoumeng Han, Dandan Yan, Ruhong Zhuang, Ben Hu, Zhan Zhang medRxiv 2020.03.22.20040758; doi: https://doi.org/10.1101/2020.03.22.20040758

Boulware DR, Pullen MF, Bangdiwala AS, et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 [published online ahead of print, 2020 Jun 3]. N Engl J Med. 2020;10.1056/NEJMoa2016638. doi:10.1056/NEJMoa2016638.

Grein J, Ohmagari N, Shin D, et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19 [published online ahead of print, 2020 Apr 10]. N Engl J Med. 2020; NEJMoa2007016. doi:10.1056/NEJMoa2007016

Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020; published online April 29. https://doi.org/10.1016/ S0140-6736(20)31022-9

Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 [published online ahead of print, 2020 May 27]. N Engl J Med. 2020;10.1056/NEJMoa2015301. doi:10.1056/NEJMoa2015301.

Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 - Preliminary Report [published online ahead of print, 2020 May 22]. N Engl J Med. 2020; NEJMoa2007764. doi:10.1056/NEJMoa2007764

Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19 [published online ahead of print, 2020 Mar 18]. N Engl J Med. 2020; NEJMoa2001282. doi:10.1056/NEJMoa2001282

Published

2020-12-01

How to Cite

SIQUEIRA, L. de O.; GELAIN, A. P.; GRANDO, L. C. K.; KREUTZ, L. C. Fármacos com potencial terapêutico para tratamento da COVID-19 / Drugs with therapeutic potential for COVID-19 treatment. Brazilian Journal of Health Review, [S. l.], v. 3, n. 6, p. 17324–17343, 2020. DOI: 10.34119/bjhrv3n6-153. Disponível em: https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/20749. Acesso em: 29 mar. 2024.

Issue

Section

Original Papers